PUBLICATION

Fluorescence intensity and lifetime imaging of lipofuscin-like autofluorescence for label-free predicting clinical drug response in cancer

Authors
Yan, Y., Xing, F., Cao, J., Hu, Y., Li, L., Gao, Z., Jia, H., Miao, K., Shao, F., Deng, C.X., Luo, K.Q., Lee, L.T.O., Liu, T.M.
ID
ZDB-PUB-221226-1
Date
2022
Source
Redox Biology   59: 102578102578 (Journal)
Registered Authors
Jia, Hao
Keywords
Apoptosis, Autofluorescence, Label-free, Lipofuscin, Necrosis
MeSH Terms
  • Animals
  • Lipofuscin*/metabolism
  • Microscopy, Fluorescence
  • Neoplasms*/diagnostic imaging
  • Neoplasms*/drug therapy
  • Staining and Labeling
  • Zebrafish/metabolism
PubMed
36566738 Full text @ Redox Biol.
Abstract
Conventional techniques for in vitro cancer drug screening require labor-intensive formalin fixation, paraffin embedding, and dye staining of tumor tissues at fixed endpoints. This way of assessment discards the valuable pharmacodynamic information in live cells over time. Here, we found endogenous lipofuscin-like autofluorescence acutely accumulated in the cell death process. Its unique red autofluorescence could report the apoptosis without labeling and continuously monitor the treatment responses in 3D tumor-culture models. Lifetime imaging of lipofuscin-like red autofluorescence could further distinguish necrosis from apoptosis of cells. Moreover, this endogenous fluorescent marker could visualize the apoptosis in live zebrafish embryos during development. Overall, this study validates that lipofuscin-like autofluorophore is a generic cell death marker. Its characteristic autofluorescence could label-free predict the efficacy of anti-cancer drugs in organoids or animal models.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping